+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer



Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer



Oncology 94(5): 311-323



The aim of this study was to clarify the usefulness of plasma exosomal microRNA-451a (miR-451a) as a novel biomarker for the early prediction of recurrence and prognosis in non-small cell lung cancer (NSCLC) patients after curative resection. Before surgery, plasma samples were collected and exosomal microRNA (miRNA) levels were evaluated. We first profiled specific exosomal miRNAs related to recurrence in 6 NSCLC patients with stage IA cancer by miRNA microarray. We then validated the usefulness of selected miRNAs as biomarkers using the other 285 NSCLC patients. Plasma exosomal miR-451a showed the highest upregulation in the NSCLC patients with recurrence in the miRNA microarray analysis. A significant positive correlation was demonstrated between exosomal miR-451a levels and NSCLC tissue miR-451a levels. Exosomal miR-451a showed a significant association with lymph node metastasis, vascular invasion, and stage. In stage I, II, or III patients, the overall survival (OS) and disease-free survival (DFS) rates among the high-exosomal-miR-451a patients were significantly worse than those among the low-exosomal-miR-451a patients. In Cox multivariate analysis, exosomal miR-451a showed significance for OS and DFS. Plasma exosomal miR-451a might serve as a reliable biomarker for the prediction of recurrence and prognosis in NSCLC patients with stage I, II, or III cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065656186

Download citation: RISBibTeXText

PMID: 29533963

DOI: 10.1159/000487006


Related references

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncology Letters 13(3): 1256-1263, 2017

Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 25(2): 155-161, 2017

MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. Plos One 10(8): E0134220, 2016

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chinese Journal of Cancer 30(6): 407-414, 2012

Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Oncotargets and Therapy 10: 4527-4534, 2017

MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. Oncology Letters 16(3): 2777-2782, 2018

Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small-cell lung cancer diagnosis. Journal of Cellular Physiology 2019, 2019

Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. International Journal of Clinical and Experimental Medicine 8(6): 9291-9298, 2015

Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis. Medical Science Monitor 24: 9307-9316, 2018

Exosome‑encapsulated microRNA‑23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage. Oncology Reports 40(1): 319-330, 2018

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59(2): 203-210, 2007

Prognosis of recurrence after complete resection in early-stage non-small cell lung cancer. Korean Journal of Thoracic and Cardiovascular Surgery 46(6): 449-456, 2013

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?: Track: Biology and Pathogenesis. Journal of Thoracic Oncology 11(10s): S219-S220, 2016

Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer. European Review for Medical and Pharmacological Sciences 23(3): 1108-1115, 2019

Plasma LUNX mRNA, a non-invasive specific biomarker for diagnosis and prognostic prediction of non-small cell lung cancer. American Journal of Cancer Research 6(2): 452-458, 2016